Search

Displaying results 8781 - 8790 of 10000 in total
  1. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  2. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  3. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  4. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  5. Drug

    Tonabersat

    go.drugbank.com/drugs/DB06578
    Investigational

  6. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

    Synonyms: 1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide, 1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide
  7. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients. … The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity.

  8. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  9. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator. … Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  10. Drug

    Creatinine

    go.drugbank.com/drugs/DB11846
    Investigational

    Creatinine has been used in trials studying the treatment of Amyotrophic Lateral Sclerosis.